The University of California, San Francisco cancer of the prostate risk assessment score: A straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy

被引:593
作者
Cooperberg, MR
Pasta, DJ
Elkin, EP
Litwin, MS
Latini, DM
DuChane, J
Carroll, PR
机构
[1] Univ Calif San Francisco, Mt Zion Canc Ctr, San Francisco, CA 94115 USA
[2] Univ Calif Los Angeles, Los Angeles, CA USA
[3] TAP Pharmaceut Prod Inc, Lake Forest, IL USA
关键词
prostatic neoplasms; risk factors; prognosis; prostate-specific antigen;
D O I
10.1097/01.ju.0000158155.33890.e7
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Multivariate prognostic instruments aim to predict risk of recurrence among patients with localized prostate cancer. We devised a novel risk assessment tool which would be a strong predictor of outcome across various levels of risk, and which could be easily applied and intuitively understood. Materials and Methods: We studied 1,439 men diagnosed between 1992 and 2001 who had undergone radical prostatectomy and were followed in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) database, a longitudinal, community based disease registry of patients with prostate cancer. Disease recurrence was defined as prostate specific antigen (PSA) 0.2 ng/ml or greater on 2 consecutive occasions following prostatectomy or a second cancer treatment more than 6 months after surgery. The University of California, San Francisco-Cancer of the Prostate Risk Assessment (UCSF-CAPRA) score was developed using preoperative PSA, Gleason score, clinical T stage, biopsy results and age. The index was developed and validated using Cox proportional hazards and life table analyses. Results: A total of 210 patients (15%) had recurrence, 145 by PSA criteria and 65 by second treatment. Based on the results of the Cox analysis, points were assigned based on PSA (0 to 4 points), Gleason score (0 to 3), T stage (0 to 1), age (0 to 1) and percent of biopsy positive cores (0 to 1). The UCSF-CAPRA score range is 0 to 10, with roughly double the risk of recurrence for each 2-point increase in score. Recurrence-free survival at 5 years ranged from 85% for a UCSF-CAPRA score of 0 to 1 (95% CI 73%-92%) to 8% for a score of 7 to 10 (95% Cl 0%-28%). The concordance index for the UCSF-CAPRA score was 0.66. Conclusions: The UCSF-CAPRA score is a straightforward yet powerful preoperative risk assessment tool. It must be externally validated in future studies.
引用
收藏
页码:1938 / 1942
页数:5
相关论文
共 20 条
  • [1] Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer
    Albertsen, PC
    Hanley, JA
    Gleason, DF
    Barry, MJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11): : 975 - 980
  • [2] The contemporary management of prostate cancer in the United States: Lessons from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), a national disease registry
    Cooperberg, MR
    Broering, JM
    Litwin, MS
    Lubeck, DP
    Mehta, SS
    Henning, JM
    Carroll, PR
    [J]. JOURNAL OF UROLOGY, 2004, 171 (04) : 1393 - 1401
  • [3] Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
    D'Amico, AV
    Whittington, R
    Malkowicz, SB
    Schultz, D
    Blank, K
    Broderick, GA
    Tomaszewski, JE
    Renshaw, AA
    Kaplan, I
    Beard, CJ
    Wein, A
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11): : 969 - 974
  • [4] Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer
    D'Amico, AV
    Whittington, R
    Malkowicz, SB
    Schultz, D
    Fondurulia, J
    Chen, MH
    Tomaszewski, JE
    Renshaw, AA
    Wein, A
    Richie, JP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (06) : 1164 - 1172
  • [5] Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: Results from the search database
    Freedland, SJ
    Aronson, WJ
    Csathy, GS
    Kane, CJ
    Amling, CL
    Presti, JC
    Dorey, F
    Terris, MK
    [J]. UROLOGY, 2003, 61 (04) : 742 - 747
  • [6] Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score
    Freedland, SJ
    Csathy, GS
    Dorey, F
    Aronson, WJ
    [J]. JOURNAL OF UROLOGY, 2002, 167 (02) : 516 - 520
  • [7] Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer
    Graefen, M
    Ohori, M
    Karakiewicz, PI
    Cagiannos, I
    Hammerer, PG
    Haese, A
    Erbersdobler, A
    Henke, RP
    Huland, H
    Wheeler, TM
    Slawin, K
    Scardino, PT
    Kattan, MW
    [J]. JOURNAL OF UROLOGY, 2004, 171 (01) : 200 - 203
  • [8] Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: Results from cancer of the prostate strategic urological research endeavor (CaPSURE)
    Greene, KL
    Meng, MV
    Elkin, EP
    Cooperberg, MR
    Pasta, DJ
    Kattan, MW
    Wallace, K
    Carroll, WR
    [J]. JOURNAL OF UROLOGY, 2004, 171 (06) : 2255 - 2259
  • [9] Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: Results from CaPSURE
    Grossfeld, GD
    Latini, DM
    Lubeck, DP
    Broering, JM
    Li, YP
    Mehta, SS
    Carroll, PR
    [J]. UROLOGY, 2002, 59 (04) : 560 - 565
  • [10] A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer
    Holmberg, L
    Bill-Axelson, A
    Helgesen, F
    Salo, JO
    Folmerz, P
    Häggman, M
    Andersson, S
    Spångberg, A
    Busch, C
    Nordling, S
    Palmgren, J
    Adami, HO
    Johansson, J
    Norlén, BJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (11) : 781 - 789